Close
  Indian J Med Microbiol
 

Figure 3: (a-d) Receiver operating characteristic curve used to predict the performance of serum anti-G antigen 1 antibody in distinguishing hepatocellular carcinoma with normal human individuals, liver cirrhosis with normal human individuals, hepatitis B with normal human individuals, and hepatocellular carcinoma with nonhepatocellular carcinoma controls. The receiver operating characteristic curve was generated using data from 59 hepatocellular carcinoma sera samples and 180 nonhepatocellular carcinoma sera samples (including 61 liver cirrhosis sera samples, 60 hepatitis B sera sample, and 59 normal human individual sera samples). The area under curve the receiver operating characteristics curve for G antigen 1 in distinguishing hepatocellular carcinoma with normal human individuals, liver cirrhosis with normal human individuals, hepatitis B with normal human individuals, and hepatocellular carcinoma with nonhepatocellular carcinoma controls was 0.776, 0.730, 0.566, and 0.733, respectively

Figure 3: (a-d) Receiver operating characteristic curve used to predict the performance of serum anti-G antigen 1 antibody in distinguishing hepatocellular carcinoma with normal human individuals, liver cirrhosis with normal human individuals, hepatitis B with normal human individuals, and hepatocellular carcinoma with nonhepatocellular carcinoma controls. The receiver operating characteristic curve was generated using data from 59 hepatocellular carcinoma sera samples and 180 nonhepatocellular carcinoma sera samples (including 61 liver cirrhosis sera samples, 60 hepatitis B sera sample, and 59 normal human individual sera samples). The area under curve the receiver operating characteristics curve for G antigen 1 in distinguishing hepatocellular carcinoma with normal human individuals, liver cirrhosis with normal human individuals, hepatitis B with normal human individuals, and hepatocellular carcinoma with nonhepatocellular carcinoma controls was 0.776, 0.730, 0.566, and 0.733, respectively